These supplements don't reliably help kids improve their cholesterol or triglyceride levels — the studies show no clear benefit.
Scientific Claim
Prebiotic, probiotic, and synbiotic supplementation shows no consistent association with improvements in total cholesterol, LDL-C, HDL-C, or triglycerides in overweight and obese children and adolescents, based on low certainty evidence.
Original Statement
“Prebiotic, probiotic, or synbiotics supplementation showed a non-significant effect on TC (SMD = −0.00; 95% CI: −0.19 to 0.19), TG (SMD = 0.04; 95% CI: −0.22 to 0.30), LDL-C (SMD = 0.00; 95% CI: −0.26 to 0.27), and HDL-C (SMD = −0.14; 95% CI: −0.54 to 0.26)... Quality of evidence was low for lipid profile outcomes.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study accurately reports non-significant effects and acknowledges low certainty. No overstatement is present.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceWhether microbiome-modulating supplements consistently improve lipid profiles in obese youth.
Whether microbiome-modulating supplements consistently improve lipid profiles in obese youth.
What This Would Prove
Whether microbiome-modulating supplements consistently improve lipid profiles in obese youth.
Ideal Study Design
A GRADE-assessed meta-analysis of ≥15 double-blind RCTs with 1,500+ participants, using standardized lipid panels (fasting TC, TG, LDL-C, HDL-C), stratified by intervention type, duration (>16 weeks), and baseline lipid abnormalities, with sensitivity analyses for dietary fat intake.
Limitation: Cannot determine if effects are mediated by microbiota changes or dietary confounders.
Randomized Controlled TrialLevel 1bWhether a specific synbiotic formulation improves lipid profile in obese children with dyslipidemia.
Whether a specific synbiotic formulation improves lipid profile in obese children with dyslipidemia.
What This Would Prove
Whether a specific synbiotic formulation improves lipid profile in obese children with dyslipidemia.
Ideal Study Design
A double-blind RCT of 100 obese children (aged 10–16) with LDL-C ≥130 mg/dL or TG ≥150 mg/dL, randomized to a defined synbiotic (e.g., L. plantarum 10^10 CFU + 12g inulin) or placebo for 24 weeks, with primary outcome: change in LDL-C, and secondary outcomes: HDL-C, TG, apolipoprotein B, and fecal bile acid metabolism.
Limitation: Results may not generalize to children without dyslipidemia.
Prospective Cohort StudyLevel 2bWhether habitual use of prebiotics/probiotics predicts lower risk of developing dyslipidemia in obese children.
Whether habitual use of prebiotics/probiotics predicts lower risk of developing dyslipidemia in obese children.
What This Would Prove
Whether habitual use of prebiotics/probiotics predicts lower risk of developing dyslipidemia in obese children.
Ideal Study Design
A 6-year prospective cohort of 3,000+ children (ages 5–12) with BMI ≥85th percentile, tracking supplement use via digital logs and biomarkers, with annual lipid panels and adjustment for saturated fat intake, physical activity, and family history of hyperlipidemia.
Limitation: Cannot prove causation due to confounding by diet and lifestyle.
Evidence from Studies
Supporting (1)
The role of microbiome-modulating supplements in managing metabolic syndrome risk factors among overweight and obese youth: a GRADE-assessed meta-analysis
This study looked at kids who are overweight or obese and tested whether supplements like prebiotics and probiotics changed their cholesterol and triglyceride levels — and found they didn’t. So it supports the claim that these supplements don’t reliably help with those blood fats.